MBDA: A Valuable Tool for Medical Decision Making.

MBDA: A Valuable Tool for Medical Decision Making. J Rheumatol. 2019 Jul 15;: Authors: Calabrese LH Abstract I read with interest the editorial by Dr. Roy Fleischmann on the limitations of the multibiomarker disease activity test (MBDA) in the management of rheumatoid arthritis (RA)1 He provides a comprehensive review of some of the key studies of MBDA in clinical trials and concludes that the "MBDA has not met the test of being a biomarker that can predict who will or will not respond to a specific therapy, who will or will not be able to taper or stop therapy or who will or will not have radiographic progression." PMID: 31308201 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31308201?dopt=Abstract

Source: J Rheumatol - July 14, 2019 Category: Rheumatology Authors: Calabrese LH Tags: J Rheumatol Source Type: research